Four Phase 2 investigator-initiated studies of TNX-1900 (intranasal potentiated oxytocin) are ongoing for pediatric obesity, binge eating disorder, bone health...
SAN DIEGO, March 19, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the publication of a study of...
SANTA CLARA, CA / ACCESSWIRE / March 18, 2024 / Zeto, Inc., a commercial-stage medical technology company transforming EEG brain...
First patient has been dosed in the randomized, controlled, double blind clinical trial for Autism Spectrum Disorder in pediatric patients...
TARRYTOWN, New York, March 13, 2024 (GLOBE NEWSWIRE) -- via IBN – PaxMedica, Inc. (NASDAQ:PXMD), a biopharmaceutical company focused on advancing...
Bionano will host a pre-conference scientific session that will include a live product demonstration of the Stratys™ system for high...
SANTA CLARA, CA / ACCESSWIRE / March 6, 2024 / Zeto, Inc., a commercial-stage medical technology company transforming EEG brain...
NORTH BRUNSWICK, N.J.--(BUSINESS WIRE)--LinusBio, a leader in precision exposome sequencing, today announced its inclusion in Fierce Medtech's "Fierce 15" list...
The SCI- 210 treatment is now available at clinical site for autism spectrum disorder clinical trial in pediatric patients, in...
SAN DIEGO, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that Erik Holmlin, PhD, Bionano’s...
- Amendment Reduces Bionano’s Outstanding Debt -SAN DIEGO, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (“Bionano”) (Nasdaq: BNGO)...
HITRUST Risk-Based, 2-year (r2) Certification validates Zeto is committed to strong cybersecurity and protecting sensitive dataSANTA CLARA, CA / ACCESSWIRE...
Vancouver, British Columbia--(Newsfile Corp. - February 26, 2024) - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF)...
SOMERSET, NJ / ACCESSWIRE / February 23, 2024 / Americord, a leading private stem cell bank, announced the release of...
SAN DIEGO, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), today announced that optical genome mapping (OGM) was...
Full year 2023 total revenues of $464.4 million, compared to $250.3 million in 2022 Full year 2023 CAPLYTA net product...
WAKIX® (pitolisant) Net Revenue of $168.4 Million for Fourth Quarter and $582.0 Million for Full Year 2023; Representing Growth of...
The clinical trial for SCI-210 will be conducted in Israel, after which the company aims to move forward with the...
SAN DIEGO, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced a peer-reviewed publication in Cancers from...
Pre-print publication from Levy, et al. describes the second phase of a multisite evaluation and validation of optical genome mapping (OGM) that...